Sen. Burr: FDA User Fee Agreements Advance Innovation, Bring Important Reforms Following Infant Formula Crisis
June 15, 2022
June 15, 2022
WASHINGTON, June 15 -- Sen. Richard Burr, R-North Carolina, ranking member of the Senate Health, Education, Labor and Pensions Committee, issued the following news release:
The Senate Committee on Health, Education, Labor and Pensions (HELP) held an executive session to consider S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, bipartisan legislation to reauthorize the Food and Drug Administration's (FDA) prescription drug, generic drug, b . . .
The Senate Committee on Health, Education, Labor and Pensions (HELP) held an executive session to consider S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, bipartisan legislation to reauthorize the Food and Drug Administration's (FDA) prescription drug, generic drug, b . . .